Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 November 2021Website:
http://www.vaxxinity.comNext earnings report:
16 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
VAXX Latest News
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.
Vaxxinity stock is experiencing a rise on Friday with significant pre-market trading activity, with over 21 million shares being traded at the moment.
Presentation will address the Company's clinical data in Parkinson's disease Presentation will address the Company's clinical data in Parkinson's disease
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and executives will present and participate in meetings at three upcoming medical and investor conferences in November.
The heavy selling pressure might have exhausted for Vaxxinity, Inc. (VAXX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Congress
What type of business is Vaxxinity?
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.
What sector is Vaxxinity in?
Vaxxinity is in the Healthcare sector
What industry is Vaxxinity in?
Vaxxinity is in the Biotechnology industry
What country is Vaxxinity from?
Vaxxinity is headquartered in United States
When did Vaxxinity go public?
Vaxxinity initial public offering (IPO) was on 11 November 2021
What is Vaxxinity website?
https://www.vaxxinity.com
Is Vaxxinity in the S&P 500?
No, Vaxxinity is not included in the S&P 500 index
Is Vaxxinity in the NASDAQ 100?
No, Vaxxinity is not included in the NASDAQ 100 index
Is Vaxxinity in the Dow Jones?
No, Vaxxinity is not included in the Dow Jones index
When does Vaxxinity report earnings?
The next expected earnings date for Vaxxinity is 16 July 2024